W Shi1, T Jiang1, P Nuciforo2, C Hatzis1, E Holmes3, N Harbeck4, C Sotiriou5, L Peña6, S Loi7, D D Rosa8, S Chia9, A Wardley10, T Ueno11, J Rossari8, H Eidtmann12, A Armour13, M Piccart-Gebhart5, D L Rimm1, J Baselga14, L Pusztai1. 1. Department of Breast Medical Oncology, Yale University, Yale Cancer Center, New Haven, USA. 2. Vall d'Hebron Institute of Oncology, Barcelona, Spain. 3. Frontier Science, Inverness, Scotland. 4. Breast Center, Department of Obstetrics and Gynecology, University of Munich, Germany. 5. Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. 6. Spanish Breast Cancer Cooperative Group SOLTI, Barcelona, Spain. 7. Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Australia. 8. Hospital Moinhos de Vento, Porto Alegre, Brazil. 9. Department of Medical Oncology, BC Cancer Agency, Vancouver, Canada. 10. The Christie/NIHR Clinical Research Facility, Manchester, UK. 11. Department of Breast Surgery, Kyoto University Hospital, Kyoto, Japan. 12. Department of Obstetrics and Gynecology, Campus Kiel, University Hospital Kiel, Kiel, Germany. 13. Novartis, Cambridge. 14. Memorial Sloan-Kettering Cancer Center, Memorial Hospital, New York, USA.
Abstract
Background: We performed whole-exome sequencing of pretreatment biopsies and examined whether genome-wide metrics of overall mutational load, clonal heterogeneity or alterations at variant, gene, and pathway levels are associated with treatment response and survival. Patients and Methods: Two hundred and three biopsies from the NeoALTTO trial were analyzed. Mutations were called with MuTect, and Strelka, using pooled normal DNA. Associations between DNA alterations and outcome were evaluated by logistic and Cox-proportional hazards regression. Results: There were no recurrent single gene mutations significantly associated with pathologic complete response (pCR), except PIK3CA [odds ratio (OR) = 0.42, P = 0.0185]. Mutations in 33 of 714 pathways were significantly associated with response, but different genes were affected in different individuals. PIK3CA was present in 23 of these pathways defining a ‘trastuzumab resistance-network’ of 459 genes. Cases with mutations in this network had low pCR rates to trastuzumab (2/50, 4%) compared with cases with no mutations (9/16, 56%), OR = 0.035; P < 0.001. Mutations in the ‘Regulation of RhoA activity’ pathway were associated with higher pCR rate to lapatinib (OR = 14.8, adjusted P = 0.001), lapatinib + trastuzumab (OR = 3.0, adjusted P = 0.09), and all arms combined (OR = 3.77, adjusted P = 0.02). Patients (n = 124) with mutations in the trastuzumab resistance network but intact RhoA pathway had 2% (1/41) pCR rate with trastuzumab alone (OR = 0.026, P = 0.001) but adding lapatinib increased pCR rate to 45% (17/38, OR = 1.68, P = 0.3). Patients (n = 46) who had no mutations in either gene set had 6% pCR rate (1/15) with lapatinib, but had the highest pCR rate, 52% (8/15) with trastuzumab alone. Conclusions: Mutations in the RhoA pathway are associated with pCR to lapatinib and mutations in a PIK3CA-related network are associated with resistance to trastuzumab. The combined mutation status of these two pathways could define patients with very low response rate to trastuzumab alone that can be augmented by adding lapatinib or substituting trastuzumab with lapatinib.
RCT Entities:
Background: We performed whole-exome sequencing of pretreatment biopsies and examined whether genome-wide metrics of overall mutational load, clonal heterogeneity or alterations at variant, gene, and pathway levels are associated with treatment response and survival. Patients and Methods: Two hundred and three biopsies from the NeoALTTO trial were analyzed. Mutations were called with MuTect, and Strelka, using pooled normal DNA. Associations between DNA alterations and outcome were evaluated by logistic and Cox-proportional hazards regression. Results: There were no recurrent single gene mutations significantly associated with pathologic complete response (pCR), except PIK3CA [odds ratio (OR) = 0.42, P = 0.0185]. Mutations in 33 of 714 pathways were significantly associated with response, but different genes were affected in different individuals. PIK3CA was present in 23 of these pathways defining a ‘trastuzumab resistance-network’ of 459 genes. Cases with mutations in this network had low pCR rates to trastuzumab (2/50, 4%) compared with cases with no mutations (9/16, 56%), OR = 0.035; P < 0.001. Mutations in the ‘Regulation of RhoA activity’ pathway were associated with higher pCR rate to lapatinib (OR = 14.8, adjusted P = 0.001), lapatinib + trastuzumab (OR = 3.0, adjusted P = 0.09), and all arms combined (OR = 3.77, adjusted P = 0.02). Patients (n = 124) with mutations in the trastuzumab resistance network but intact RhoA pathway had 2% (1/41) pCR rate with trastuzumab alone (OR = 0.026, P = 0.001) but adding lapatinib increased pCR rate to 45% (17/38, OR = 1.68, P = 0.3). Patients (n = 46) who had no mutations in either gene set had 6% pCR rate (1/15) with lapatinib, but had the highest pCR rate, 52% (8/15) with trastuzumab alone. Conclusions: Mutations in the RhoA pathway are associated with pCR to lapatinib and mutations in a PIK3CA-related network are associated with resistance to trastuzumab. The combined mutation status of these two pathways could define patients with very low response rate to trastuzumab alone that can be augmented by adding lapatinib or substituting trastuzumab with lapatinib.
Authors: Roberto Salgado; Carsten Denkert; Christine Campbell; Peter Savas; Paolo Nuciforo; Paolo Nucifero; Claudia Aura; Evandro de Azambuja; Holger Eidtmann; Catherine E Ellis; Jose Baselga; Martine J Piccart-Gebhart; Stefan Michiels; Ian Bradbury; Christos Sotiriou; Sherene Loi Journal: JAMA Oncol Date: 2015-07 Impact factor: 31.777
Authors: Daniel E Carvajal-Hausdorf; Kurt A Schalper; Lajos Pusztai; Amanda Psyrri; Konstantine T Kalogeras; Vasiliki Kotoula; George Fountzilas; David L Rimm Journal: J Natl Cancer Inst Date: 2015-05-19 Impact factor: 13.506
Authors: J-Y Pillé; C Denoyelle; J Varet; J-R Bertrand; J Soria; P Opolon; H Lu; L-L Pritchard; J-P Vannier; C Malvy; C Soria; H Li Journal: Mol Ther Date: 2005-02 Impact factor: 11.454
Authors: Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov Journal: Proc Natl Acad Sci U S A Date: 2005-09-30 Impact factor: 11.205
Authors: Maurizio Scaltriti; Paolo Nuciforo; Ian Bradbury; Jeff Sperinde; Dominique Agbor-Tarh; Christine Campbell; Ahmed Chenna; John Winslow; Violeta Serra; Josep Lluis Parra; Ludmila Prudkin; José Jimenez; Claudia Aura; Nadia Harbeck; Lajos Pusztai; Catherine Ellis; Holger Eidtmann; Joaquin Arribas; Javier Cortes; Evandro de Azambuja; Martine Piccart; José Baselga Journal: Clin Cancer Res Date: 2014-12-02 Impact factor: 12.531
Authors: Edith A Perez; E Aubrey Thompson; Karla V Ballman; S Keith Anderson; Yan W Asmann; Krishna R Kalari; Jeanette E Eckel-Passow; Amylou C Dueck; Kathleen S Tenner; Jin Jen; Jian-Bing Fan; Xochiquetzal J Geiger; Ann E McCullough; Beiyun Chen; Robert B Jenkins; George W Sledge; Eric P Winer; Julie R Gralow; Monica M Reinholz Journal: J Clin Oncol Date: 2015-01-20 Impact factor: 44.544
Authors: Ryan L Powles; Vikram B Wali; Xiaotong Li; William E Barlow; Zeina Nahleh; Alastair M Thompson; Andrew K Godwin; Christos Hatzis; Lajos Pusztai Journal: Clin Cancer Res Date: 2020-01-09 Impact factor: 12.531
Authors: Maki Tanioka; Cheng Fan; Joel S Parker; Katherine A Hoadley; Zhiyuan Hu; Yan Li; Terry M Hyslop; Brandelyn N Pitcher; Matthew G Soloway; Patricia A Spears; Lynn N Henry; Sara Tolaney; Chau T Dang; Ian E Krop; Lyndsay N Harris; Donald A Berry; Elaine R Mardis; Eric P Winer; Clifford A Hudis; Lisa A Carey; Charles M Perou Journal: Clin Cancer Res Date: 2018-07-23 Impact factor: 12.531